Tian Jing
Director of Finance/CFO at Winhealth Pharma Group Co. Ltd.
Profile
Tian Jing is a Managing Director at LYFE Capital.
Tian started his career at McKinsey, moving onto Goldman Sachs NY office as an investment banker in healthcare industry.
He then became the Director of Investments at Novartis NJ office, leading him to be a Managing Director at Fosun NY office.
Upon joining LYFE, Jing has brought us his well-rounded skill sets in the capital markets, corporation running and global healthcare investments.
Jing received his MBA in Finance and Healthcare from Yale University School of Management and his undergrad in international economics from Fudan University and University of Hong Kong.
Tian Jing active positions
| Companies | Position | Start |
|---|---|---|
Zhouling Private Equity Fund Management (Shanghai) Co., Ltd.
 Zhouling Private Equity Fund Management (Shanghai) Co., Ltd. Investment ManagersFinance Zhouling Private Equity Fund Management (Shanghai) Co Ltd (LYFE Capital) is a private equity/venture capital firm founded in 2015 by James Zhao. The firm is headquartered in Shanghai, China. | Director/Board Member | 01/01/2021 |
Winhealth Pharma Group Co. Ltd.
 Winhealth Pharma Group Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Winhealth Pharma Group Co. Ltd. is a Chinese innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The company is based in Hangzhou, China. Winhealth Pharma Group has established long-term strategic partnerships with dozens of world-leading biotechnology companies, including Roche, Pfizer, Kyowa Kirin, Shionogi, Cumberland Pharmaceutical, and Daiichi-Sankyo. It has built a unique, balanced, and diversified portfolio with numerous orphan drugs and specialty products at commercial and late clinical stages, and will continuously look to bring in more innovative therapies from the globe. The company was founded in 2006 by Cherry Hu and Jack Wang. Jack Wang has been the CEO since 2006. | Director of Finance/CFO | 01/01/2020 |
Former positions of Tian Jing
| Companies | Position | End |
|---|---|---|
| NOVARTIS AG | Director of Investments | - |
Fosun International Holdings Ltd.
 Fosun International Holdings Ltd. Financial ConglomeratesFinance Fosun International Holdings Ltd. operates as an investment holding company. The company is headquartered in Road Town, British Virgin Islands. | Director/Board Member | - |
| THE GOLDMAN SACHS GROUP, INC. | Investment Committee Member | - |
Training of Tian Jing
| University of Hong Kong | Undergraduate Degree |
| Yale University | Masters Business Admin |
| Fudan University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| THE GOLDMAN SACHS GROUP, INC. | Finance |
| NOVARTIS AG | Health Technology |
| Private companies | 3 |
|---|---|
Fosun International Holdings Ltd.
Fosun International Holdings Ltd. Financial ConglomeratesFinance Fosun International Holdings Ltd. operates as an investment holding company. The company is headquartered in Road Town, British Virgin Islands. | Finance |
Zhouling Private Equity Fund Management (Shanghai) Co., Ltd.
Zhouling Private Equity Fund Management (Shanghai) Co., Ltd. Investment ManagersFinance Zhouling Private Equity Fund Management (Shanghai) Co Ltd (LYFE Capital) is a private equity/venture capital firm founded in 2015 by James Zhao. The firm is headquartered in Shanghai, China. | Finance |
Winhealth Pharma Group Co. Ltd.
Winhealth Pharma Group Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Winhealth Pharma Group Co. Ltd. is a Chinese innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The company is based in Hangzhou, China. Winhealth Pharma Group has established long-term strategic partnerships with dozens of world-leading biotechnology companies, including Roche, Pfizer, Kyowa Kirin, Shionogi, Cumberland Pharmaceutical, and Daiichi-Sankyo. It has built a unique, balanced, and diversified portfolio with numerous orphan drugs and specialty products at commercial and late clinical stages, and will continuously look to bring in more innovative therapies from the globe. The company was founded in 2006 by Cherry Hu and Jack Wang. Jack Wang has been the CEO since 2006. | Commercial Services |
- Stock Market
- Insiders
- Tian Jing
